BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
Keyword: Aflibercept
1
Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture
4/9/2021 8:11:25 AM | Browse: 596 | Download: 994
2
Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer
2/22/2019 4:33:37 AM | Browse: 948 | Download: 983
3
Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy
2/22/2019 4:33:37 AM | Browse: 849 | Download: 863
4
FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer
9/14/2018 11:38:00 AM | Browse: 953 | Download: 1296
5
Role of targeted therapy in metastatic colorectal cancer
9/12/2016 10:43:00 AM | Browse: 976 | Download: 1382
6
Treatment of diabetic retinopathy: Recent advances and unresolved challenges
8/23/2016 8:55:00 AM | Browse: 996 | Download: 1463
7
New active drugs for the treatment of advanced colorectal cancer
12/24/2015 8:55:00 AM | Browse: 883 | Download: 1405
8
Curing diabetic retinopathy: Is a strategy emerging?
11/13/2015 3:33:00 PM | Browse: 1105 | Download: 1567
9
Anti-angiogenic therapies for metastatic colorectal cancer: Current and future perspectives
9/11/2014 8:40:00 PM | Browse: 987 | Download: 1352
10
Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema
9/1/2014 2:50:00 PM | Browse: 969 | Download: 979
11
Advances and new perspectives in the treatment of metastatic colon cancer
8/26/2014 4:37:00 PM | Browse: 1081 | Download: 1186
Write to the Help Desk
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345